[{"orgOrder":0,"company":"Sotio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"SOT109","moa":"CDH17","graph1":"Oncology","graph2":"Preclinical","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sotio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sotio \/ Inapplicable"},{"orgOrder":0,"company":"Sotio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"SOT102","moa":"CLDN18.2","graph1":"Oncology","graph2":"Preclinical","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sotio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sotio \/ Inapplicable"},{"orgOrder":0,"company":"Sotio","sponsor":"LegoChem Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Antibody-drug Conjugate","year":"2022","type":"Agreement","leadProduct":"SOT106","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sotio \/ LegoChem Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Sotio \/ LegoChem Biosciences"},{"orgOrder":0,"company":"Sotio","sponsor":"Synaffix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Antibody-drug Conjugate","year":"2025","type":"Licensing Agreement","leadProduct":"SOT112","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sotio \/ Synaffix","highestDevelopmentStatusID":"4","companyTruncated":"Sotio \/ Synaffix"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : under the license and option agreement with Synaffix. Sotio will obtain the Synaffix’s technology to develop two bispecific antibody-drug conjugate (ADC) programs.

                          Product Name : SOT112

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Undisclosed

                          March 13, 2025

                          Lead Product(s) : SOT112

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Synaffix

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          02

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : SOT109 is a next-genaration antibody-drug conjugate targeting Cadherin-17 (CDH17), which is currently being evaluated for the treatment of Colorectal Cancer.

                          Product Name : SOT109

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Inapplicable

                          March 03, 2025

                          Lead Product(s) : SOT109

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : SOT106 is a novel ADC based on SOTIO Biotech’s proprietary antibodies and LCB’s industry-leading ConjuAll™ ADC platform technology with potential best-in class efficacy, safety and tolerability currently in preclinical development against multiple ...

                          Product Name : SOT106

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Undisclosed

                          November 29, 2022

                          Lead Product(s) : SOT106

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : LegoChem Biosciences

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          04

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : SOT102 demonstrated favorable tolerability and pharmacokinetic properties, with the latter substantiated by observed half-lives in the range of eight days and 13 days in cynomolgus monkey and rat, respectively.

                          Product Name : SOT102

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Inapplicable

                          December 04, 2021

                          Lead Product(s) : SOT102

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank